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ABSTRACT 
 
IBD is a gastro-intestinal disorder marked with chronic inflammation of intestinal epithelium, dam- 
aging mucosal tissue and manifests into several intestinal and extra-intestinal symptoms. Currently 
used medical therapy is able to induce and maintain the patient in remission, however no modifies or 
reverses the underlying pathogenic mechanism. The research of other medical approaches is crucial 
to the treatment of IBD and, for this, it´s important to use animal models to mimic the characteristics 
of disease in real life. The aim of the study is to develop an animal model of TNBS-induced colitis to 
test new pharmacological approaches. TNBS was instilled intracolonic single dose as described by 
Morris et al. It was administered 2,5% TNBS in 50% ethanol through a catheter carefully inserted into 
the colon. Mice were kept in a Tredelenburg position to avoid reflux. On day 4 and 7, the animals 
were sacrificed by cervical dislocation. The induction was confirmed based on clinical symp-
toms/signs, ALP determination and histopathological analysis. At day 4, TNBS group presented a 
decreased body weight and an alteration of intestinal motility characterized by diarrhea, severe 
edema of the anus and moderate morbidity, while in the two control groups weren’t identified any 
alteration on the clinical symptoms/signs with an increase of the body weight. TNBS group presented 
the highest concentrations of ALP comparing with control groups. The histopathology analysis 
revealed severe necrosis of the mucosa with widespread necrosis of the intestinal glands. Severe 
hemorrhagic and purulent exsudates were observed in the submucosa, muscular and serosa. TNBS 
group presented clinical symptoms/ signs and histopathological features compatible with a correct 
induction of UC. The peak of manifestations became maximal at day 4 after induction. This study 
allows concluding that it’s possible to develop a TNBS- induced colitis 4 days after instillation. 
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RESUMO 
 
DII é um distúrbio gastro-intestinal caracterizado por inflamação crónica do epitélio intestinal com 
dano associado da mucosa, manifestando-se a partir de sintomas intestinais e extra-intestinais. A 
terapia médica utilizada é capaz de induzir e manter o doente em remissão, mas não modifica ou 
inverte o mecanismo patogénico subjacente. A procura de outras abordagens terapêuticas é crucial 
para o tratamento de DII e, para tal, é importante o uso de modelos animais para mimetizar as 
características da doença. O objetivo do estudo é desenvolver um modelo animal de colite induzida 
por TNBS de modo a testar novas abordagens farmacológicas. O TNBS foi instilado por via intra-
colónica em dose única como descrito por Morris et al. Foi administrado 2,5% de TNBS em 50% de 
etanol através de um cateter inserido no cólon. Os animais foram mantidos em posição Tredelenburg 
para evitar o refluxo. Nos dias 4 e 7, os animais foram sacrificados por deslocamento cervical. A 
indução de colite foi caracterizada com base nos sintomas/sinais clínicos, determinação de ALP e 
análise histopatológica. No dia 4, o grupo TNBS apresentou uma diminuição do peso corporal e uma 
alteração da motilidade intestinal caracterizada por diarreia, edema severo do ânus e morbilidade 
moderada, enquanto nos dois grupos controlo não foram identificados quaisquer alterações nos 
sintomas/ sinais clínicos com um aumento do peso corporal. O grupo TNBS apresentou as maiores 
concentrações de ALP, comparando com os grupos controlo. A análise histopatológica demonstrou 
necrose grave da mucosa com necrose generalizada das glândulas intestinais. Foi observado 
exsudato hemorrágico e purulento ao nível da submucosa, muscular e serosa. O grupo TNBS apre-
sentou sintomas/sinais clínicos e características histopatológicas compatíveis com uma correta indu-
ção de colite. O pico das manifestações tornou-se máximo ao 4º dia após a indução. Este estudo per-
mite concluir que é possível desenvolver colite induzida por TNBS 4 dias após a instilação. 
Palavras-Chaves: DII, Colite induzida por TNBS, Inflamação, Vias metabólicas, Alvos farmacológicos. 
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INTRODUTION 
Inflammatory bowel diseases (IBD), which in-
clude Crohn’s disease (CD) and ulcerative colitis 
(UC), are chronic inflammatory diseases of the 
gastrointestinal tract, characterized by chronic 
recur- rent ulceration of the bowels1. IBD 
affects between 7–10% of people worldwide, 
mainly of Caucasian descent2,3, promoting 
significant gastrointestinal symptoms, like 
bloody diarrhea, abdominal pain, anemia, 
weight loss and other extra-intestinal manifesta-
tions1. Interplay between several factors, like 
genetic predisposition, environmental trigger 
and aberrant immune reaction seem to 
contribute to initiation and progression of IBD4,5. 
Pathogenesis of IBD is not fully understood, 
but two broad hypotheses have arisen regarding 
its fundamental nature. The first contends that 
primary dysregulation of the mucosal immune 
system leads to excessive immunologic respon-
ses to normal microflora. The second suggests 
that changes in the composition of gut micro-
flora and/or deranged epithelial barrier function 
elicit pathologic responses from the normal 
mucosal immune system. Currently, it’s well 
accepted that IBD is indeed characterized by an 
abnormal mucosal immune response but that 
microbial factors and epithelial cell abnor-
malities can facilitate this response6. 
Currently used medical therapy of IBD 
consists of salicylates, corticosteroids, immune-
suppressants and immunomodulators. These 
drug treatments aim to induce and maintain the 
patient in remission and ameliorate the disea-
se’s secondary effects, rather than modifying or 
reversing the underlying pathogenic mecha-
nism1,7. Second-generation agents have been 
developed with improved drug delivery, increa-
sed efficacy and decreased side effects 
frequency1. However, their use may result in 
severe side effects and complications, such as 
an increased rate of malignancies or infectious 
diseases7. The research of other medical 
approaches is crucial to the treatment of IBD 
and, for this, it is important to use animal 
models to mimic the characteristics of disease in 
real life8. 
Animal models are widely used to study 
pathogenesis of human diseases and to test new 
therapeutics9. Most of these models are based 
either on chemical induction, immune cell trans-
fer or gene targeting4. Trinitrobenzene sulfonic 
acid (TNBS) promotes a chemical induction of 
colitis by intrarectal instillation of the haptena-
ting substances TNBS dissolved in ethanol 
resulting in acute inflammation with ulcers in rat 
and mouse10. The acute transmural damage 
became maximal from 3 days to 1 week after 
instillation, and resolved within 2 weeks8,10-12. 
The protocols of the TNBS-induced IBD model 
are not standardized, such as the dosage of 
TNBS, the depth of TNBS administration, and 
the time point for model evaluation. Therefore, 
it knows that the effects of TNBS are dose 
dependent8. Thus, the aim of the study is to 
develop an animal model of TNBS-induced 
colitis to test new pharmacological approaches. 
 
MATERIAL AND METHODS 
Materials 
TNBS 5% aqueous solution was purchased 
from Sigma Chemical Co. Ketamine (Imalgene® 
1000) was purchased from Merial. Xilazine 
(Rompun® 2%) was purchased from Bayer. 
ADVIA® kit was purchased from Siemens 
Healthcare Diagnostics. 
 
Animals 
Male CD-1 mice, 30-40 g in weight and 5-6 
weeks of age, were housed in standard polypro-
pylene cages with ad libitum access to food and 
water in the Faculty of Pharmacy Central Animal 
Facility in the University of Lisbon. 
 
Experimental groups 
Three groups of mice were used in the study, 
which received an intracolonic administration of 
different preparations. The first group (n = 6) 
received 100 µl of 2.5% of TNBS in 50% ethanol 
(TNBS group) for induction of TNBS-colitis. The 
second group (n=3) received 100µl of 50% 
ethanol (ethanol group). The third group (n=2) 
received 100µl of saline solution (sham group). 
It was used two control animals groups, namely 
ethanol and sham group. 
 
Induction of TNBS-colitis 
TNBS was instilled intracolonic single dose as 
described by Morris et al (1989). Briefly, mice 
were left unfed during 24h. In the induction day, 
mice were anesthetized with Ketamine 
100mg/Kg + Xilazine 10mg/Kg IP and a catheter 
was carefully inserted into the colon until the tip 
was 4 cm proximal to the anus. Then, 2,5% TNBS 
in 50% ethanol was administered and mice were 
kept for 1 min in a Tredelenburg position to 
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avoid reflux13,14. On day 4 and 7, the animals 
were sacrificed by cervical dislocation, however 
a cardiac puncture was made immediately 
before in order to obtain samples for determi-
nation of serum alkaline phosphatase (ALP). The 
abdomen was opened by a midline incision. The 
small intestine and colon were removed, freed 
from surrounding tissues and washed with 
phosphate buffered saline. The results between 
day 4 and 7 were subsequently compared. 
 
Clinical symptoms/signs 
The animals were observed daily, monitoring 
body weight, morbidity, stool consistency and 
anus appearance. 
 
Biochemical Marker 
ALP in the sample catalyzes the hydrolysis of 
colorless p-nitrophenyl phosphate to give p-       
-nitrophenol and inorganic phosphate. At the pH 
of the assay (10.3 e 10.4), the p-nitrophenol is in 
the yellow phenoxide form. The rate of absor-
bance increase at 410/478 nm is directly propor-
tional to the ALP activity in the sample. Optimi-
zed concentrations of zinc and magnesium ions 
are present to activate the ALP in the sample. 
The measurement was made by an automatic 
analyzer: ADVIA 1200. 
 
Histopathological analysis 
Histopathology was carried out by an inde- 
pendent histopathologist of the Faculty of Ve-
terinary Medicine of Universidade Lusófona de 
Humanidades e Tecnologias. The intestine sam-
ples were fixed in 10% neutral buffered forma-
lin, processed routinely for paraffin embedding, 
sectioned at 5µm, and stained with hematoxylin 
and eosin. The morphological features of small 
intestine and colon were evaluated in the same 
conditions for all studied groups (TNBS group, 
ethanol group and sham group), according the 
number of days after induction and the 
localization of sections. It was evaluated at day 
4 and 7, with several sections of small intestine 
due to its length and with three sections of 
colon (proximal to the cecum, in the middle of 
the colon and distal to the rectum). 
 
Microscopic assessment of colitis severity 
The assessment of colitis severity was based 
on previously described parameters15: 
a)epithelial damage (0 = none, 1 = minimal 
loss of goblet cells, 2 = extensive loss of goblet 
cells, 3 = minimal loss of crypts and extensive 
loss of gob-let cells, and 4 = extensive loss of 
crypts); 
b)infiltration (0 = none, 1 = infiltrate around 
crypt bases, 2 = infiltrate in muscularis mucosa, 
3 = extensive infiltrate in muscularis mucosa 
with edema, and 4 = infiltration of submucosa). 
The histological activity index (HAI) was 
calculated as the sum of the epithelium and 
infiltration score, resulting in the total HAI score 
ranging from 0 (unaffected) to 8 (severe colitis). 
 
RESULTS 
Monitoring of clinical symptoms/signs 
Animals were observed daily for morbidity, 
stool consistency and anus appearance. At day 
1, TNBS group presented an alteration of 
intestinal motility characterized by diarrhea or 
soft stools, severe edema of the anus and 
moderate morbidity. Ethanol group showed the 
same clinical signs, but lightly. At day 4 and 7, 
TNBS group kept the observed clinical signs, 
while in the ethanol group wasn’t identified any 
alteration. Sham group remained without any 
alterations during the study. 
Regarding body weight, ethanol and sham 
groups increased the weight of mice during the 
study, but TNBS group showed a decreased 
body weight at day 4 (TABLE 1). 
 
Table 1. Average of body weight during the study 
 
AVERAGE OF BODY WEIGHT ± SD (g) 
DAY 0 DAY 4 DAY 7 
TNBS GROUP 
(n=6) 
 
34.3 ± 4.7 
 
29 ± 0 
 
43.3 ± 4.6 
ETHANOL 
GROUP 
(n=3) 
 
33.6 ± 1.6 
 
44 ± 0 
 
40.5 ± 2.5 
SHAM GROUP 
(n=2) 
37 ± 2 43 ± 0 47 ± 0 
 
At day 2, there were 2 deaths in the TNBS 
group. The macroscopic analysis showed a 
severe obstruction to the colon filled with large 
fecal pellets. Severe swelling of the intestinal 
wall, inflammation with presence of generalized 
strokes. The lesions were apparently consistent 
with toxic megacolon. 
 
Biochemical Marker 
ALP was identified in all experimental 
groups, but in different concentrations depen-
ding of the group was evaluated. TNBS group 
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presented the highest values around 32.9 ± 5.5 
U/L of serum concentration comparing with the 
other two groups. Ethanol and sham groups 
presented decreased values but quite similar 
around 10.8±1.5 U/L and 8.5±0 U/L, respecti-
vely. 
 
Assessment of small intestine lesions 
The small intestine was analyzed and it 
showed similar histological results among 
evaluated groups and the number of days after 
induction. Apparently, no macroscopic lesions 
were observed, but microscopically, a slight lym-
phoplasmacytic infiltrate in the lamina propria 
was identified and it was similar to all studied 
groups independently of the day after induction 
(Figure 1). 
 
 
Figure 1. Histopathological features of small intestine 
sections (100x) from (a) TNBS group, (b) Ethanol 
group, (c)Sham group. 
 
Assessment of colitis severity 
The colon was analyzed and it showed 
different histological results depending of which 
group was evaluated and the number of days 
after induction. Regarding macroscopic evalua-
tion of colon, it was observed hemorrhagic 
focus and edema. Microscopically, the TNBS 
group presented severe lesions at day 2 and day 
4, whereas no substantial morphological chan-
ges were detected at day 7 (Figure 2). The histo-
pathology analysis revealed severe necrosis of 
the mucosa with widespread necrosis of the 
intestinal glands. The remaining intestinal 
glands were ectasic with squamous metaplasia. 
Severe hemorrhagic and purulent exsudates 
were observed in the submucosa, muscular and 
serosa. 
The assessment of colitis severity was based 
on two main parameters namely (a) epithelial 
damage and (b) infiltration. At day 2 and 4, it 
was observed the higher score (HAI of 8 – 
severe colitis) for all samples evaluated on the 
TNBS group comparatively to the samples of 
ethanol and sham group, which it was observed 
no lesions (HAI of 0-unaffected). 
 
Figure 2. Morphologic changes of colon from TNBS 
group in day (a) 2, (b) 4 and (c) 7. In the ethanol and 
sham group, no histological alterations were obser-
ved in the colon (HAI of 0–unaffected), indepen-
dently of the day after induction (Figure 3). 
 
 
Figure 3. Histopathological features of colon (40x) 
from Ethanol group and (b) Sham group, in day 4 and 
7. 
 
DISCUSSION 
The pathogenesis of IBD is similar between 
human disease and TNBS-induced colitis16, and 
this is the reason why so many research groups 
are now using this model to investigate novel 
approaches for the treatment of IBD. 
Regarding monitoring of clinical symptoms/ 
signs, TNBS group presented an alteration of 
intestinal motility characterized by diarrhea or 
soft stools, severe edema of the anus and 
moderate morbidity, while ethanol and sham 
groups remained without any alterations. These 
clinical manifestations in the TNBS group were 
expected and compatible with a correct 
induction of UC15,16. The manifestations became 
maximal at day 4 after induction and resolved at 
day 7. The literature refers that manifestations 
became maximal from 3 days to 1 week after 
instillation, and resolved within 2 weeks8,10-12, 
depending of the dosage of TNBS, the depth of 
TNBS administration, and the time point for 
model evaluation8. The peak of clinical sym-
ptoms/signs is also confirmed by the decreased 
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body weight of TNBS group at day 4, comparing 
with ethanol and sham groups that increased its 
body weight during the study. 
ALP is regularly measured in clinical practice 
and its changes in serum levels are observed in a 
number of clinical conditions of organs where it 
can be found like bone, liver, bowel and 
kidney17. Therefore, ALP was measured in all 
experimental groups and TNBS group presented 
the highest values around 32.9 ± 5.5 U/L of 
serum concentration comparing with ethanol 
and sham groups (10.8±1.5 U/L and 8.5±0 U/L, 
respectively). The low concentrations of APL in 
both control groups (ethanol and sham group) 
suggest that the origin of increased APL in the 
TNBS group is due to intestinal lesion inducted 
in this study. These our results are consistent 
with other studies, which observed a higher AP 
activity in the colon from colitic animals 
compared to the non-colitic animals from acute 
intestinal inflammation model induced by 
TNBS18,19. Intestinal ALP has been considered a 
phenotypic marker of differentiation, which is 
up-regulated in experimental chronic diarrhea 
and IBD19,20. It’s a small intestinal brush-border 
enzyme that functions as a gut mucosal defense 
factor, providing resistance to bacterial invasion 
when the intestine is subject to a certain lesion 
like local or distant ischemic injury21. Based on 
these results, administration of exogenous 
intestinal ALP enzyme to patients with the 
active form of IBD may be a therapeutic 
option22. 
The histopathological analysis showed a 
slight lymphocytic inflammatory infiltrate in the 
lamina propria similar with all experimental 
groups. These lesions are consistent with a sub-
acute to chronic process, suggesting no 
relationship with this study. Perhaps, the reason 
is that mice are not Specific Pathogen Free, even 
because there are similar for all experimental 
groups. These should therefore be devalued. 
The morphological features of colon in the 
TNBS group were evaluated at day 2, 4 and 7. 
The results revealed severe lesions of tissue 
between day 2 and day 4, whereas it was 
detected no substantial morphological changes 
at day 7. The peak of clinical symptoms/signs is 
also confirmed by the severe lesions at day 4. 
No histological alterations were observed in the 
colon from ethanol group and sham group. The 
histopathology analysis revealed severe necrosis 
of the mucosa with widespread necrosis of the 
intestinal glands. The remaining intestinal 
glands were ectasic with squamous metaplasia. 
Severe hemorrhagic and purulent exsudates 
were observed in the submucosa, muscular and 
serosa. These lesions are consistent with a 
correct induction of UC by TNBS15,16. 
 
CONCLUSION 
This study allows concluding that it’s possible 
to develop a TNBS-induced colitis 4 days after 
instillation. This model will be interesting to 
clarify the inflammatory mechanisms associated 
with IBD in order to propose other pharma-
cological modulation of the inflammatory 
response than the currently known, with the 
main objective to facilitate a more effective and 
selective treatment for this disease. 
 
REFERÊNCIAS BIBLIOGRÁFICAS 
1.Pithadia A, Jain S. Treatment of inflammatory 
bowel disease (IBD). Pharmacological Reports. 
2011; 63:629-42 
2.Hanauer S. Inflammatory bowel disease: epi-
demiology, pathogenesis, and therapeutic 
opportunities. Inflamm Bowel Dis. 2006; 12(1): 
3–9 
3.Spiegel B. The burden of IBS: looking at 
metrics. Curr Gastroenterol Rep. 2009; 11:265–9 
4.Wirtz S, Neurath M. Mouse models of 
inflamma- tory bowel disease. Adv Drug Del Rev. 
2007; 59:1073–83 
5.Mayer L. Evolving paradigms in the 
pathogenesis of IBD. J Gastroenterol. 2010; 
45:9–16 
6.Strober W. Fuss I, Mannon P. The fundamental 
basis of inflammatory bowel disease. J Clin 
Invest. 2007; 117:514–21 in doi: 10.1172/ 
JCI30587 
7.Engel M, Neurath M. New pathophysiological 
in-sights and modern treatment of IBD. J 
Gastroenterol. 2010; 45:571-83 
8.Qin H, Wu J, Tong X, Sung J, Xu H, Bian Z. 
Systematic review of animal models of post-
infectious/ post-inflammatory irritable bowel 
syndrome. J Gastroenterol. 2011; 46:164–74 
9.Szczepanik M, Góralska M, Marciñska K, 
Wiacek M, Strzepa A, Dorozynska I, Szczepanik 
M. Epicutaneous immunization with protein an- 
tigen TNP-Ig alleviates TNBS-induced colitis in 
mice. Pharmacological Reports. 2012; 64: 1497-504 
10.Morris G, Beck P, Herridge M, Depew W, 
Szewczuk M, Wallace J. Hapten-induced model 
of chronic inflammation and ulceration in the  
 
Acta Farmacêutica Portuguesa, 2013, vol. 2, n. 2 
95 
rat colon. Gastroenterology. 1989; 96:795–803 
11.Linden D, Foley K, McQuoid C, Simpson J, 
Shar- key K, Mawe G. Serotonin transporter 
function and expression are reduced in mice 
with TNBS-induced colitis. Neurogastroenterol 
Motility. 2005; 17:565–74 
12.Lamb K, Zhong F, Gebhart G, Bielefeldt K. 
Exper- imental colitis in mice and sensitization 
of con- verging visceral and somatic afferent 
pathways. Am J Physiol Gastrointest Liver 
Physiol. 2006; 290:G451–7 
13.Wirtz S, Neufert C, Weigmann B, Neurath 
14.M. Chemically induced mouse models of in- 
testinal inflammation. Nat Protocols. 2007; 2: 
541–6 
15.Mazzon E, Muià C, Paola D, Genovese T, 
Menegazzi M, De Sarro A, Suzuki H, Cuzzocrea 
16.S. Green tea polyphenol extract attenuates 
colon injury induced by experimental colitis. 
Free Radic Res. 2005; 39(9):1017-25 
17.Alex P, Zachos N, Nguen T, Gonzales L, Chen 
T-E, Conklin L, Centola M, Li X. Distinct cytokine 
patterns identified converging visceral and so- 
matic afferent pathways. American Journal of 
Physiology - Gastrointestinal and Liver Physiol- 
ogy from multiplex profiles of murine DSS and 
TNBS-induced colitis. Inflamm Bowel Dis. 2009; 
15:341–52 
18.Pawar P, Gilda S, Sharma S, Jagtap S, 
Paradkar A, Mahadik K, Ranjekar P, Harsulkar A. 
Rectal gel ap- plication of Withania somnifera 
root extract ex- pounds anti inflammatory and 
mucorestorative activity in TNBS-induced 
Inflammatory Bowel Disease. BMC Complement 
Altern Med. 2011; 11(34):1-9 
19.Tinnion R, Embleton N. How to use.alkaline 
phosphatase in neonatology. Archives of Dis-
ease in Childhood–Education and Practice.2012; 
97(4):157-63 in doi:10.1136/archdischild-2012-
301633 
20.Cruz T, Gálvez J, Crespo E, Ocete M,  Zarzuelo 
21.Effects of silymarin on the acute stage of the 
trinitrobenzene sulphonic acid model of rat 
colitis. Planta Medica. 2001; 67:94-6 
22.Luchini A, Rodrigues-orsi P, Cestari S, Seito L, 
Witaicenis A, Pellizzon C, Stasi L. Intestinal Anti-
inflammatory Activity of Coumarin and 4-Hy- 
droxycoumarin in the Trinitrobenzenesulphonic 
Acid Model of Rat Colitis. Biol Pharm Bull. 2008; 
31(7):1343-50 
23.Galvéz J, de la Cruz J, Zarzuelo A, Sánchez de 
la Cuesta F. Flavonoid inhibition of enzymic and 
nonenzymic lipid peroxidation in rat liver differs 
from its influence on the glutathione-related en- 
zymes. Pharmacology. 1995; 51:127-33 
24.Ramasamy S, Nguyen D, Eston M, Alam S, 
Moss A, Ebrahimi F, Biswas B, Mostafa G, Chen 
K, Kaliannan K, Yammine H, Narisawa S, Millán J, 
Warren H, Hohmann E, Mizoguchi E, Reinecker 
H, Bhan A, Snapper S, Malo M, Hodin R. 
Intestinal alkaline phosphatase has beneficial 
effects in mouse models of chronic colitis. 
Inflamm Bowel Dis. 2011;  17(2):532–42 in doi: 
10.1002/ibd.21377 
25.Molnár K, Vannay A, Szebeni B, Bánki N, 
Sziksz E, Cseh A, Gyórffy H, Lakatos P, Papp M, 
Arató A, Veres G. Intestinal  alkaline phospha-
tase in the colonic mucosa of children with 
inflammatory bowel disease. World J 
Gastroenterol. 2012; 18(25):3254-9 
 
